decisionhealth Newsletters, Part B News - 2003 Issue 12 (December)
$500 million oral cancer demo good for doctors, patients
Subscribe or sign in to view the full article.
Article Overview
This article explains a Medicare demonstration project tied to cancer care and broader non-covered drug payment issues. It is aimed at physicians, oncology practices, coders, and reimbursement professionals who need to understand how the demonstration could affect billing patterns, patient access, and Medicare administration. The piece discusses the program’s scope, the types of therapies under consideration, stakeholder reactions, and implementation timing.
Why This Topic Matters
The demonstration could affect oncology reimbursement, Medicare-covered drug payment policy, and the volume and type of physician billing associated with cancer care. It is relevant to practices monitoring federal payment policy changes and their potential operational impact.
What You Will Learn
- How the Medicare demonstration is expected to affect oncology reimbursement and billing
- What broad categories of therapies and non-covered drugs are discussed in relation to the program
- Which stakeholders are commenting on the demonstration and why
- Why implementation timing and program details are important to providers and patients
Who Should Read This
- Oncology practices
- Medical coders and billers
- Reimbursement specialists
- Physician administrators
- Health policy analysts
- Pharmaceutical reimbursement professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com